27
Nov
2017
Female Contraception, Health and Liberty
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Nov
2017
You Went to SITC And All You Got Was This TR Post? (Part 1)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2017
How Will the Great Sex Predator Purge Alter Gender Dynamics at Work?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Nov
2017
Former Lilly Exec To Lead HHS, a Flurry of FDA Approvals, & Gates Bets $100M on Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2017
The Oxygen-Providing, High-Autonomy M&A Model: A Sign of Things to Come
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Nov
2017
Sage’s Salvo At Postpartum Depression, Sarepta’s Two Steps Ahead, & Barron Jumps to GSK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Nov
2017
The Long Run Podcast: Elias Zerhouni on the Role of Immigrants In Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2017
The Dark Underbelly of Startup Fundraising: Working Through Self-Doubt, Loneliness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2017
Amazon Prowling the Drug Supply Chain, Celgene’s Ho-Hum Bounceback & a Couple More IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2017
Understanding Polio, Baseball and Cancer: Sometimes the “When” is as Vital as the “What”
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Oct
2017
Atlas, Amgen, Lilly Bet $30M for Kymera’s Imaginative Protein Degradation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Oct
2017
Activist FDA Boss Zeroes in on Opioid Crisis, PTC Shot Down, and CRISPR 2.0 Buzz
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2017
VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch
Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson... Read More
25
Oct
2017
Richard Pops on Fighting the Opioid Painkiller Crisis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2017
AbbVie Shells Out $205M Upfront for Alector’s Antibodies Vs. Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Oct
2017
BioMarin Book Contains Rare Insight Into the Rare Disease Business
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2017
Gilead’s Thrilling CAR-T Victory, Celgene’s Agonizing Crohn’s Defeat, & Vir Goes Big
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Oct
2017
Vir Biotechnology, a ‘Shock and Awe’ Startup, Bets on Infectious Disease with $500M+
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2017
VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2017
Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.